Quintiles, Sinclair ink 10-year partnership to commercialize portfolio in Mexico

Wednesday, September 19, 2012 11:37 AM

Quintiles, a fully integrated biopharmaceutical services company, and Sinclair IS Pharma, a topicals and supportive care specialist, have signed a 10-year collaboration and licensing agreement for Quintiles (Rowfarma Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.

Quintiles will handle the entire process including regulatory submissions; product importation, warehousing and distribution to wholesalers; sales force promotion to dermatologists and plastic surgeons; and marketing, advertising and promotion.

“This collaboration, a further step in Latin America, supports our company’s growth strategy: to move our product portfolio into fast-growing, emerging markets through strategic, regional partnerships,” said Chris Spooner, CEO of Sinclair IS Pharma. “Quintiles’ extensive commercialization experience and proven track record in Mexico and other emerging markets made it the clear choice to help us execute our strategy.”

The Sinclair portfolio includes: Atopiclair, for the treatment of mild to moderate atopic dermatitis; Kelo-cote silicone-gel scar reduction range, for the prevention and management of abnormal scars; Sebclair, for the treatment of seborrhoeic dermatitis; Bio-Taches, for hyperpigmentation disorders; XClair, for the treatment of radiation dermatitis; and Papulex, for the management and maintenance of mild to moderate acne.

“Our customers are thinking carefully about their strategy in emerging markets, and are looking for a trusted partner who can help navigate the complexities these markets present,” said James Featherstone, senior vice president of commercial strategy, Quintiles. “With this agreement, Quintiles will work on a wide range of services—from registration through to launch, to help Sinclair expand its geographic footprint in a more predictable manner.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs